Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors.


Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
Historique:
received: 04 07 2020
accepted: 29 09 2020
pubmed: 6 1 2021
medline: 23 11 2021
entrez: 5 1 2021
Statut: ppublish

Résumé

Idiopathic pleuroparenchymal fibroelastosis (PPFE) is a rare form of idiopathic interstitial pneumonia that is characterized by predominantly upper lobe pleural and subpleural lung parenchymal fibrosis. Pneumothorax is one of the major respiratory complications in PPFE patients; however, its clinical features are poorly understood. We aimed to investigate the complication of pneumothorax in patients with idiopathic PPFE. A retrospective multicenter study involving 89 patients who had been diagnosed with idiopathic PPFE was conducted. We investigated the cumulative incidence, clinical features, and risk factors of pneumothorax after the diagnosis of idiopathic PPFE. Pneumothorax developed in 53 patients (59.6%) with 120 events during the observation period (41.8 ± 35.0 months). The cumulative incidence of pneumothorax was 24.8, 44.9, and 53.9% at 1, 2, and 3 years, respectively. Most events of pneumothorax were asymptomatic (n = 85; 70.8%) and small in size (n = 92; 76.7%); 30 patients (56.6%) had recurrent pneumothorax. Chest drainage was required in 23 pneumothorax events (19.2%), and a persistent air leak was observed in 13 (56.5%). Patients with pneumothorax were predominantly male and frequently had pathological diagnoses of PPFE and prior history of pneumothorax and corticosteroid use; they also had significantly poorer survival than those without pneumothorax (log-rank test; p = 0.001). Multivariate analysis revealed that a higher residual volume/total lung capacity ratio was significantly associated with the development of pneumothorax after the diagnosis. Pneumothorax is often asymptomatic and recurrent in patients with idiopathic PPFE, leading to poor outcomes in some cases.

Sections du résumé

BACKGROUND BACKGROUND
Idiopathic pleuroparenchymal fibroelastosis (PPFE) is a rare form of idiopathic interstitial pneumonia that is characterized by predominantly upper lobe pleural and subpleural lung parenchymal fibrosis. Pneumothorax is one of the major respiratory complications in PPFE patients; however, its clinical features are poorly understood.
OBJECTIVE OBJECTIVE
We aimed to investigate the complication of pneumothorax in patients with idiopathic PPFE.
METHODS METHODS
A retrospective multicenter study involving 89 patients who had been diagnosed with idiopathic PPFE was conducted. We investigated the cumulative incidence, clinical features, and risk factors of pneumothorax after the diagnosis of idiopathic PPFE.
RESULTS RESULTS
Pneumothorax developed in 53 patients (59.6%) with 120 events during the observation period (41.8 ± 35.0 months). The cumulative incidence of pneumothorax was 24.8, 44.9, and 53.9% at 1, 2, and 3 years, respectively. Most events of pneumothorax were asymptomatic (n = 85; 70.8%) and small in size (n = 92; 76.7%); 30 patients (56.6%) had recurrent pneumothorax. Chest drainage was required in 23 pneumothorax events (19.2%), and a persistent air leak was observed in 13 (56.5%). Patients with pneumothorax were predominantly male and frequently had pathological diagnoses of PPFE and prior history of pneumothorax and corticosteroid use; they also had significantly poorer survival than those without pneumothorax (log-rank test; p = 0.001). Multivariate analysis revealed that a higher residual volume/total lung capacity ratio was significantly associated with the development of pneumothorax after the diagnosis.
CONCLUSION CONCLUSIONS
Pneumothorax is often asymptomatic and recurrent in patients with idiopathic PPFE, leading to poor outcomes in some cases.

Identifiants

pubmed: 33401281
pii: 000511965
doi: 10.1159/000511965
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-26

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Masato Kono (M)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, masato.k@sis.seirei.or.jp.
Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan, masato.k@sis.seirei.or.jp.

Yutaro Nakamura (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yasunori Enomoto (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hideki Yasui (H)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hironao Hozumi (H)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Masato Karayama (M)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yuzo Suzuki (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Kazuki Furuhashi (K)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yoshihiro Miki (Y)

Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Dai Hashimoto (D)

Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Tomoyuki Fujisawa (T)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Noriyuki Enomoto (N)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Naoki Inui (N)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yusuke Kaida (Y)

Department of Respiratory Medicine, Enshu Hospital, Hamamatsu, Japan.

Koshi Yokomura (K)

Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.

Naoki Koshimizu (N)

Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.

Mikio Toyoshima (M)

Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.

Shiro Imokawa (S)

Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.

Takashi Yamada (T)

Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.

Toshihiro Shirai (T)

Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.

Hiroshi Hayakawa (H)

Department of Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan.

Hidenori Nakamura (H)

Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Takafumi Suda (T)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH